Evidence map›Paper›PMID 34129082›Full record

ArticleApplied microbiology and biotechnology2021

A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen.

Barbara Kubickova, Jörg A Schenk, Franziska Ramm, Kornelija Markuškienė, Jochen Reetz, Paul Dremsek, Paulius Lukas Tamosiunas, Laima Cepulyte, Hoai Anh Trinh, Johannes Scholz and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Rat hepatitis E virus (Emerging microbes & infections · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 4 countries.

Barbara KubickovaInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany.
Jörg A SchenkHybrotec GmbH, 14476, Potsdam, Germany.
Franziska RammBranch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany.
Kornelija MarkuškienėInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany.
Jochen ReetzGerman Federal Institute for Risk Assessment, 10589, Berlin, Germany.
Paul DremsekInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany.
Paulius Lukas TamosiunasInstitute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania.
Laima CepulyteInstitute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania.
Hoai Anh TrinhBranch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany.
Johannes ScholzGerman Federal Institute for Risk Assessment, 10589, Berlin, Germany.
Henry Memczakqpa bioanalytics GmbH, 10585, Berlin, Germany.
Marc Hovestädtqpa bioanalytics GmbH, 10585, Berlin, Germany.
René RyllInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany.
Rasa Petraityte-BurneikieneInstitute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania.
Victor M CormanInstitute of Virology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
Anika AnderssonUP Transfer GmbH an der Universität Potsdam, 14469, Potsdam, Germany.
Dietmar BecherMicromun GmbH, 17489, Greifswald, Germany.
Martin H GroschupInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany.
Stefan KubickBranch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany.
Frank SellrieHybrotec GmbH, 14476, Potsdam, Germany.
Reimar JohneGerman Federal Institute for Risk Assessment, 10589, Berlin, Germany.
Rainer G UlrichInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany. rainer.ulrich@fli.de.ORCID http://orcid.org/0000-0002-5620-1528
Friedrich-Loeffler-Institut · DEUniversity of Potsdam · DEFederal Institute for Risk Assessment · DEVilnius University · LTFraunhofer Institute for Cell Therapy and Immunology · DEGerman Center for Infection Research · DEMicromun · DESurflay Nanotec (Germany) · DE

Funding

Bundesinstitut für Risikobewertung 1322-686Bundesministerium für Gesundheit ZMVI1-2516-AUK-701 / BMG: 321-4471-02/157DZIF TTU "Emerging Infections"
6 · The paper itself

Abstract

To generate a hepatitis E virus (HEV) genotype 3 (HEV-3)-specific monoclonal antibody (mAb), the Escherichia coli-expressed carboxy-terminal part of its capsid protein was used to immunise BALB/c mice. The immunisation resulted in the induction of HEV-specific antibodies of high titre. The mAb G117-AA4 of IgG1 isotype was obtained showing a strong reactivity with the homologous E. coli, but also yeast-expressed capsid protein of HEV-3. The mAb strongly cross-reacted with ratHEV capsid protein derivatives produced in both expression systems and weaker with an E. coli-expressed batHEV capsid protein fragment. In addition, the mAb reacted with capsid protein derivatives of genotypes HEV-2 and HEV-4 and common vole hepatitis E virus (cvHEV), produced by the cell-free synthesis in Chinese hamster ovary (CHO) and Spodoptera frugiperda (Sf21) cell lysates. Western blot and line blot reactivity of the mAb with capsid protein derivatives of HEV-1 to HEV-4, cvHEV, ratHEV and batHEV suggested a linear epitope. Use of truncated derivatives of ratHEV capsid protein in ELISA, Western blot, and a Pepscan analysis allowed to map the epitope within a partially surface-exposed region with the amino acid sequence LYTSV. The mAb was also shown to bind to human patient-derived HEV-3 from infected cell culture and to hare HEV-3 and camel HEV-7 capsid proteins from transfected cells by immunofluorescence assay. The novel mAb may serve as a useful tool for further investigations on the pathogenesis of HEV infections and might be used for diagnostic purposes. KEY POINTS: • The antibody showed cross-reactivity with capsid proteins of different hepeviruses. • The linear epitope of the antibody was mapped in a partially surface-exposed region. • The antibody detected native HEV-3 antigen in infected mammalian cells.

Indexed as

Hepatitis E virusAnimalsAntibodies, MonoclonalCapsidCapsid ProteinsCHO CellsCricetinaeCricetulusEscherichia coliHumansMiceMice, Inbred BALB CAntibodies, MonoclonalCapsid ProteinsbatHEVCell-free synthesisCross-reactivitycvHEVHepatitis E virusHEV-1HEV-2HEV-3HEV-4HEV-7Monoclonal antibodyratHEV

Identifiers

PMID34129082
PMCPMC8236046
OpenAlexW3168534425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.